The catalytic (C) subunit of cAMP-dependent protein kinase requires two distinct surfaces to form a stable complex with its physiological inhibitors, the regulatory (R) subunits and the heat-stable protein kinase inhibitors. In addition to a substrate-like segment that is common to both inhibitors, R requires a peripheral recognition site, PRS2. This surface is comprised of the essential phosphorylation site, Thr-197, His-87, Trp-196, and several surrounding basic residues. To probe the role of Trp-196 in the recognition of R, Trp-196 was replaced with Arg and Ala. Although both rC(W196A) and rC(W196R) were inhibited readily with cAMP-free R, they failed to form an inhibited holoenzyme complex with native R under conditions in which wild-type holoenzyme formed readily. Pairing rC(W196R) with mutant forms of R lacking domain B or having defects in cAMP binding sites A or B highlighted the importance of the conformation of R, and, in particular, the accessibility of site A. One of these mutants, rR(R333K), having a defect in cAMP binding site B formed a stable complex with rC(W196R) in the absence of cAMP. However, unlike wild-type holoenzyme, this complex was active.
1 is a tightly regulated enzyme that plays a multitude of roles in growth regulation, gene transcription, and metabolism. Of equal physiological importance to the specificity of this enzyme for its protein substrates is its ability to be turned on and off in response to cellular signals. There are two known physiological inhibitors of cAPK, the regulatory subunits (RI and RII) and the heat-stable protein kinase inhibitors (PKIs) (1) . The cooperative binding of cAMP to the inactive tetrameric holoenzyme, (R 2 C 2 ), causes the complex to dissociate, releasing two active catalytic subunits (C) and a dimeric regulatory subunit saturated with four molecules of cAMP (R 2 cAMP 4 ). PKIs interact only with the free C subunit and carry, in addition to a cAPK inhibition site, a nuclear export signal that shuttles the complex actively out of the nucleus (2) .
The R subunits and PKIs inhibit C by a common mechanism. Both contain an inhibitory consensus sequence, RRXS/T⌿, that is shared by most substrates and inhibitors of cAPK, where the phosphorylation (P) site is either Ser, Thr, or Ala, X is any amino acid, and ⌿, at the P ϩ 1 site, is a hydrophobic residue. In RI and PKI, the P site is an Ala, whereas in RII, this site is a phosphorylatable Ser (3) (4) (5) . This consensus site sequence binds competitively to the active site cleft and is similar for both R and PKI. However, this interaction is not sufficient to achieve high affinity binding. Binding to C is bipartite. Both R and PKI require an additional interaction site.
As indicated in Fig. 1 , the C subunit contains two distinct additional surfaces on the large lobe that are important for recognition of PKI and R. One surface, referred to here as peripheral recognition site 1 (PRS1), is essential for high affinity binding of PKI, and another is required for high affinity binding of R. The interactions that account for the high affinity of C and PKI are well defined in the crystal structure of C containing the 20 amino acid inhibitor peptide, IP20, derived from residues 5-24 of PKI (6 -8) . Replacement of the P-11 Phe and the P-6 Arg in PKI (9) as well as mutation of Arg-133, located near the PRS1 surface on C (10), all abolished high affinity binding of PKI. The realization that mutation of Arg-133 did not interfere with binding of RI indicated that other surfaces were important. In the absence of a crystal structure, many approaches have been used to map the surface that is important for R binding and at the same time to identify the regions of R that are essential for tight binding to C.
The surface on the C subunit that is important for high affinity binding of R is referred to here as peripheral recognition site 2, PRS2 (Fig. 1 ). This surface is dominated by the essential phosphorylation site, Thr-197, located on the activation loop. The importance of this phosphorylation site for regulation was originally identified in yeast (11, 12) . The PRS2 surface is quite basic, and several of these basic residues, identified originally by charge to Ala scanning mutagenesis in the yeast C homolog, TPK1, specifically Lys-213 and Lys-217, are important for R/C interaction (13) . 2 H87Q, W196R, T197A, and L198K/S were also identified using an in vivo genetic screen in human JEG-3 cells as mutations that disrupted regulation of C by RI and RII but not PKI (15, 16) . Mutation of either His-87 or Thr-197, in recombinantly expressed C, sub-sequently confirmed the importance of these residues for holoenzyme formation (17) (18) (19) . These amino acids thus define a basic surface with a node at the center comprised of Thr-197, His-87, and Trp-196. Thr-197, as discussed previously, is linked through hydrogen bonds to the active site and is important for assembly of the active conformation of this loop (19 -21) . His-87, on the other hand, located at the beginning of the C-helix in many protein kinases in the small lobe, interacts directly with Thr(P)-197 only in the closed conformation of the C subunit (22) . Trp-196 is fully exposed on the surface.
To understand further the importance of the PRS2 surface, and, in particular, Trp-196, this exposed tryptophan was replaced with Arg and Ala in recombinantly expressed murine C␣. The Ala mutation was designed to remove the hydrophobic character of Trp-196 without introducing a positive charge. Mutation of the site corresponding to Trp-196 in TPK1, Tyr-240, to Ala also disrupted R/C interaction in yeast (13) . The mutant C subunits were characterized for their kinetic properties and their ability to associate with PKI, RI, and RII. In addition, the W196R mutant C subunit was paired with mutant forms of RI, containing deletions as well as defects in their cAMP binding properties. These mutant pairs highlight the conformational flexibility of the R subunits and the important role this plays in the formation of the inhibited holoenzyme complex.
EXPERIMENTAL PROCEDURES
Materials-Reagents were purchased as follows: ATP, Mes, MOPS, and Tris (Sigma); restriction endonucleases, T4 ligase, and T7 polymerase (U. S. Biochemical Corp. or Life Technologies, Inc.); radioactive nucleotides (Amersham Corp. or NEN Life Science Products, Inc.); media supplies (Difco). The peptide substrate, LRRASLG, was synthesized at the Peptide and Oligonucleotide Facility at the University of California, San Diego. Oligonucleotides were synthesized with an Applied Biosystem DNA synthesizer, model 380B. The following bacterial strains were used: Escherichia coli DH5␣, E. coli JM101 (ATCC), E. coli BL21-DE3 (gift from William Studier of Brookhaven National Laboratories, Upton, NY), and E. coli E222. The following vectors were used: phagemid pUC119 (ATCC), PRSET-B (Invitrogen), and PLWS-3 (23) .
Mutagenesis-Mutations in the C subunit were introduced as described by Kunkel (24) using the C subunit expression vector, PRSET-B (Invitrogen). Trp-196 was replaced with Arg and Ala. The mutant C subunits, rC(W196R) and rC(W196A), were expressed in E. coli BL21-(DE3) as described previously (23) . Mutations in RI, RI(R209K) (25) , RI(R333K) (26) , RI(⌬1-91) (27) , RI(⌬260 -379) (28) , and RI(⌬261-379), were constructed in the phagemid, pUC118, as described previously.
Protein Purification-Wild-type and mutant C subunits, rC(W196R) and rC(W196A), were purified from E. coli by phosphocellulose chromatography using standard procedures (29) . rC(WT) and rC(W196A) were further purified by Mono-S gel filtration (30) . Purified C subunits (1 mg/ml) were stored at 4°C. Purity was confirmed by SDS-polyacrylamide gel electrophoresis (31) and isoelectric focusing (32) . Concentrations were determined using absorbance at 280 nm with an extinction coefficient of 1.2 and by titration with the heat-stable protein kinase inhibitor (PKI).
Wild-type (RI) and mutant regulatory subunits were overexpressed in E. coli 222 (33) and purified using anion exchange chromatography (DE52) as described previously (34, 35) . Pooled fractions from the DE52 column were subjected to a second ammonium sulfate precipitation and further purified by fast protein liquid chromatography gel filtration on Superdex 200. The RI subunits were frozen in 20 mM potassium phosphate, 2 mM EDTA, 30% glycerol, and 5 mM ␤-ME and stored at Ϫ20°C. RII was purified using a cAMP column as described by Scott et al. (36) followed by Mono-Q anion exchange chromatography using FPLC. The concentration and purities of the R subunits were determined by absorbance at 280 nm using an extinction coefficient of 1.0 and by SDSpolyacrylamide gel electrophoresis. cAMP was removed from the wildtype R subunits by urea-induced unfolding as described previously (37) .
Kinetic Assay-Enzymatic activity was measured spectrophotometrically (38) . The K m values for ATP and peptide substrate were determined using Michaelis-Menten kinetics. Typically, 20 nM C subunit was pre-equilibrated with buffer containing 1 mM ATP, 10 mM MgCl 2 , 1 mM phosphoenolpyruvate, 0.3 mM NADH, lactate dehydrogenase (12 units), and pyruvate kinase (4 units) in a final volume of 1 ml. Reactions were initiated by adding varying amounts of Kemptide (LRRASLG). The peptide substrate concentration was determined by turnover with the C subunit under conditions of limiting peptide. To determine the K m for ATP, C subunit was pre-equilibrated in assay mix containing saturating amounts of Kemptide (200 M), and the reaction was initiated by adding varying amounts of ATP. K m values and V max were determined using the curve-fitting program, KaleidaGraph TM . Thermal Stability Assay-C subunit was exchanged into KMOPS 150 (20 mM MOPS, 150 mM KCl, 1 mM dithiothreitol, pH 7.0) using NAP10 columns pre-equilibrated with the same buffer. Aliquots (15 l, 0.15 mg/ml) were placed into thin-walled polymerase chain reaction tubes, stored on ice, heated to specified temperatures for 3 min using a polymerase chain reaction programmable thermal controller (M. J. Research Inc., model PTC100), and returned to ice. Aliquots (10 l) were then assayed in 1 ml of assay mix for catalytic activity using the coupled enzyme spectrophotometric assay. To compare the T m values, the temperature corresponding to 50% inhibition, the percent activities of heated versus unheated samples were plotted against temperature.
Inhibition of Mutant C Subunits-Two methods were used to study the inhibition of C. The first method utilized a spectrophotometric inhibition assay where a fixed concentration of C (20 nM) was incubated with increasing concentrations of either RI or PKI in assay mix (1 ml) for 1 min at room temperature prior to the addition of Kemptide substrate. Since the K d values for the wild-type R 2 C 2 and PKI⅐C complexes are well below the 20 nM concentration of C used in the assay, the inhibition curves were linear and stoichiometric with PKI and with R subunits that had been stripped of cAMP with urea. Purified R subunit, in contrast, is saturated with cAMP and does not titrate in a linear manner under these conditions. R/C interaction was also measured using equilibrium dialysis. For this method, cAMP-saturated RI or RII (R 2 cAMP 4 ) (3 M) and C (2 M) (volume ϭ 0.8 ml) were dialyzed against buffer A (25 mM potassium phosphate, 100 M ATP, 500 M MgCl 2 , 5% glycerol, 5 mM ␤-ME, pH 6.5) for RI or buffer B (25 mM potassium phosphate, 5% glycerol, 5 mM ␤-ME, pH 6.5) for RII at 22°C to remove cAMP, eventually shifting the equilibrium of Reaction 1 to the right.
Aliquots (30 l) were removed at the indicated times and assayed for catalytic activity in the absence of cAMP (100 M) using the coupled spectrophotometric assay by Cook et al. (38) . The dialysis experiments were carried out with a small excess of R 2 (cAMP) 4 to drive holoenzyme formation to completion. To obtain inhibition for the wild-type subunits in the dialysis assay, cAMP must be removed, as the initial concentration of cAMP is sufficiently high to compete with the formation of holoenzyme. In the case of wild-type holoenzyme, an inhibited complex formed after about 10 h of dialysis at room temperature. At 4°C, holoenzyme does not form even in 10 h due to the very slow off-rate of cAMP (39) . When cAMP is stripped from R with urea, holoenzyme forms stoichiometrically and immediately and no dialysis is required. The dialysis experiments were always carried out in duplicate with wild-type R and C as a control. The results are typically highly reproducible. Apparent Activation Constants (K a ) for cAMP-Apparent activation constants, K a(cAMP) , were determined according to Herberg et al. (27) . Wild-type and mutant holoenzymes were prepared with 1.2 M C subunit and 1.0 M R subunit by dialysis overnight at room temperature against buffer B (20 mM potassium phosphate, 100 mM KCl, 5 mM ␤-ME, 5% glycerol, 100 mM ATP, 1 mM MgCl 2 , pH 6.5). Holoenzyme (30 nM) was incubated for 5 min at room temperature with cAMP (1-365 M) in assay mix (1 ml) prior to the addition of Kemptide substrate. Activity was then measured using the spectrophotometric assay.
Analytical Gel Filtration-R (2.8 M) and C (0.9 M) were incubated in the presence of 100 M ATP and 500 M MgCl 2 (MgATP) and loaded onto a Superose 12 gel filtration column pre-equilibrated with buffer C (20 mM MOPS, 150 mM KCl, 100 M ATP, 500 M MgCl 2 , 5 mM ␤-ME, pH 7.0). Peaks were collected and assayed for catalytic activity in the absence and presence of 100 M cAMP using the spectrophotometric coupled enzyme assay. To avoid dilution of the isolated holoenzyme, concentrated assay mix, containing NADH, pyruvate kinase, lactate dehydrogenase, phosphoenolpyruvate, and Kemptide, was used such that only 18 l was added to 500 l of holoenzyme to initiate activity.
Surface Plasmon Resonance-Surface plasmon resonance was used to study the interaction between the C subunits, rC(WT) and rC(W196R), and the R subunits, rRI(WT) and rRI(R333K), using a BIAcore instrument (Pharmacia/Biosensor) (40) . rC(WT) and rC(W196R) were coupled to a sensor chip by direct amine coupling to the CM dextran surface (Biosensor Amine Coupling Kit) as described previously (27) . About 300 response units of each C subunit were immobilized under identical conditions. All runs were performed at 23°C in 20 mM MOPS, 150 mM KCl, 100 M ATP, 1 mM MgCl 2 , 0.5 mM dithiothreitol, 0.005% P20, pH 7.0. Following each run, the surface was regenerated by injection of 10 l of 10 M cAMP and 4 mM EDTA in 20 mM MOPS, 150 mM KCl, 0.005% P20, pH 7.0.
Kinetic constants were calculated using the BIAcore pseudo-first order rate Equation 1,
where k a is the association rate, k d is the dissociation rate, C is the concentration of the injected analyte, and R is the response. Plots of dR/dt versus Rt have a slope of k s . When k s is plotted against C, the resulting slope is equal to the k a . The dissociation rate, k d , was calculated by integrating the rate equation when C ϭ 0, yielding ln(
. Affinity constants were calculated from the equation
Association rate calculations were performed using concentrations between 30 and 500 nM for the R subunits, rRI(WT) and rRI(R333K), each of which were stripped of cAMP prior to injection. The dissociation rates were calculated over the time interval, 605.5-694.5 s, for each sensogram and represent an average of five injections at five different concentrations (31.25, 62.5, 125, 250, and 500 nM) of R subunit.
RESULTS
Expression and Purification of Mutant C Subunits-To investigate its role in R/C interaction, Trp-196 was replaced with Ala and Arg in recombinantly expressed murine C ␣ . The mutant proteins, rC(W196R) and rC(W196A), were purified from E. coli using phosphocellulose chromatography as described under "Experimental Procedures." rC(W196R) was extremely stable and retained 90% of its activity after storage for 1 year at 4°C at 1 mg/ml concentrations in the original P-11 elution buffer. Similar to rC(WT), the mutant C subunits were resolved into two major isoforms following Mono-S chromatography (30) . The dominant isoform, II, is phosphorylated on Ser-10, Ser-338, and Thr-197, and isoform I is phosphorylated on four sites (Ser-10, Ser-139, Ser-338, and Thr-197). The identification of these isoforms was confirmed by isoelectric focusing. Table I , the steady-state kinetic parameters of rC(W196A) and rC(W196R) are compared with wild-type C. The K m values for ATP and peptide and the k cat values for rC(W196A) and rC(W196R) were all similar to wild-type C, consistent with the location of Trp-196 on the crystal structure of C where it is exposed and removed from the active site.
Kinetic Characterization and Thermal Stability of Mutant C Subunits-In
To establish that mutation of Trp-196 did not cause major alterations in the structure, the thermal stability of rC(W196R) was also compared with rC(WT) as described under "Experimental Procedures." The T m for rC(W196R), 43°C, was 3°C less than the T m for rC(WT).
Inhibition with RI, RII, and PKI-Although the kinetic properties of rC(W196R) and rC(W196A) resembled rC(WT), its capacity to interact with inhibitors did not. As seen in Fig. 2 , when rC(W196R) was dialyzed with either RI or RII no holoenzyme formed even after 20 h. rC(W196A) was somewhat better but was still very defective in its ability to interact with wildtype RI. Thus, both mutant C subunits were incapable of competing effectively for the R subunit in the presence of cAMP.
In contrast, when cAMP was stripped from the R subunit, both mutant C subunits titrated with cAMP-free RI in a linear and stoichiometric manner. Titration with PKI was also linear and stoichiometric, indicating that the K d values for the mutant C subunits for both PKI and wild-type RI were well below 20 nM, the concentration of C used in the assay.
Surface plasmon resonance was used to measure the actual K d for RI and rC(W196R). As shown in Table II , the K d for rC(W196R) and cAMP-free rRI(WT) was 0.6 nM, which represents an overall affinity that is 6-fold less than wild-type C with a K d of 0.1 nM. This decreased affinity of rC(W196R) for RI was mostly due to an 8-fold increase in the dissociation rate, whereas the association rate was similar to wild-type C. These combined results suggest that the W196R mutant is not defective in its ability to interact with R in the absence of cAMP, the 2 -Given the increase in K d as measured by surface plasmon resonance, the apparent K a for activation by cAMP was also measured. Holoenzyme was formed with rC(WT) and rC(W196R) by reassociation with stripped RI. As seen in Fig. 3 , the apparent K a for cAMP activation of the mutant holoenzyme was 18 nM, almost an order of magnitude lower than the apparent K a (K a ϭ 164 nM) determined for wild-type holoenzyme. This is consistent with the initial dialysis results and confirms that cAMP competes more effectively for RI than does the mutant C subunit.
Inhibition of rC(W196R) with RI Mutants-In contrast to rC(W196R) which competes poorly for RI when cAMP is bound, several mutant forms of the R subunit have been engineered that have the opposite phenotype. These R subunits compete very well for C and form holoenzyme rapidly even in the presence of saturating cAMP. These "dominant negative" R mutants fall into two classes. Two had defects in their cAMP binding sites: rRI(R209K) was defective in site A and rRI(R333K) was defective in site B. Two others, rRI(⌬260 -379) and rRI(⌬261-379), had cAMP binding site B deleted. Each of these mutant R subunits, in both the spectrophotometric assay and in the dialysis assay, behaved like urea stripped RI when they were added to rC(WT). These R subunits were therefore paired with rC(W196R) to see if they could compensate for the defect introduced by the replacement of .
B Domain Deletion Mutants rRI(⌬260 -379) and rRI(⌬261-379)-
To address whether the presence of the B domain influenced the ability of R to inhibit rC(W196R), two deletion mutants were tested: rRI(⌬260 -379) and rRI(⌬261-379). These mutations removed the B domain from RI by introducing a "Stop" codon at either Trp-260 or Glu-261. Although both of these mutant R subunits inhibited rC(WT) linearly and stoichiometrically, neither was able to inhibit rC(W196R). This was true even when these mutant R subunits were stripped of cAMP. As seen in Fig. 4 , rC(W196R) as well as another regulation defective C subunit, rC(H87A), did not form a stable holoenzyme complex with rRI(⌬261-379). Even when cAMP was stripped from rRI(⌬261-379), an inhibited complex did not form. The results for rRI(⌬260 -379) were similar. Thus, the conformation of the A domain in this mutant is distinct from its conformation when the B domain is present. This difference is most striking for the stripped R subunits where in one case, using full-length rRI, holoenzyme formed readily with the rC(W196R) and in the other, using rRI(⌬261-379), it did not.
RI(R209K) and RI(R333K)-Arg-209
and Arg-333 are conserved residues in the cAMP binding domains A and B, respectively. Mutation of either Arg to Lys disrupts cAMP binding and abolishes cooperativity between the two sites (26) . Surface plasmon resonance showed that, like rRI(WT), rRI(R209K) and rRI(R333K) have K d values for C that lie in the subnanomolar range (26) . Even without being stripped of cAMP, the binding affinities for the mutant RI subunits were as high or higher than that of cAMP-free rRI(WT). Because they are defective in cAMP binding, both rRI(R209K) and rRI(R333K) exhibited activation constants that were 10-fold higher than wild-type RI (26) . Fig. 5A shows the inhibition curves of rC(W196R) and rC(WT) with rRI(R209K) and rRI(R333K). Both rRI(R209K) and rRI(R333K) failed to inhibit rC(W196R) by more than 20% under conditions where the titration of rC(WT) was linear and stoichiometric. To test whether the failure of rRI(R209K) and rRI(R333K) to inhibit rC(W196R) was due to the presence of cAMP in either of the cAMP binding domains, the mutant R subunits were stripped of cAMP as described under "Experimental Procedures" and tested for their ability to inhibit rC(W196R). As shown in Fig. 5B , the inhibition of rC(W196R) in the presence of stoichiometric amounts of cAMP-free rRI(R209K) and rRI(R333K) was only 50 and 20%, respectively. Thus, even after removing cAMP from the remaining "good" site, neither rRI(R209K) nor rRI(R333K) resembled cAMP-free rRI(WT) in their ability to inhibit rC(W196R). Fig. 5B for rC(W196R) and rRI(R333K) plateaued at a steady-state level of approximately 40%, suggesting that rC(W196R) might be forming a stable but active complex with the mutant R subunit. Two methods were used to determine whether a stable complex formed between rC(W196R) and rRI(R333K). As indicated in Fig. 6 , when a mixture of rC(W196R) and cAMP-free rRI(R333K) was loaded [cAMP] . Holoenzyme at a concentration of 40 nM C subunit was assayed for activity in the presence of varying amounts of cAMP ranging from 1 nM to 365 M as described under "Experimental Procedures."
Isolation of an rC(W196R)⅐rRI(R333K) Complex-The inhibition curve shown in

FIG. 4. Inhibition of rC(W196R) with rRI(⌬261-379).
Inhibition assays were performed as described under "Experimental Procedures" with 25 nM rC(WT) (q), rC(W196R) (f), or rC(H87A) (OE) and increasing amounts of rRI(⌬261-379). Inset, inhibition of rC(WT) (q) and rC(W196R) (f) with cAMP-free rRI(⌬261-379).
onto a Superose 12 gel filtration column nearly all of the C subunit eluted as a complex comparable to holoenzyme. No significant amount of free C subunit was observed.
When the complex was eluted from the gel filtration column, its activity was also measured. The assay was carried out so that the concentration of the complex remained high. Thus, at 200 nM the complex had activity that was approximately 48% that of the free C subunit.
Surface plasmon resonance was used to measure the actual K d for formation of this complex. As seen in Table II , the K d was 0.9 nM with the increase due to the faster off-rate. Thus, the affinity of rC(W196R) for rRI(R333K) is very similar to its affinity for wild-type RI in the absence of cAMP.
Kinetics of the rC(W196R)⅐rRI(R333K)
Complex-Based on gel filtration, rC(W196R) and rRI(R333K) clearly formed a complex that, in the absence of cAMP, was still relatively active. To determine whether the reduced activity was due to a decrease in k cat or to an increase in the K m for peptide, rC(W196R) was combined with cAMP-free rRI(R333K) in a 1:4 molar ratio of C:R. Under these conditions, inhibition was approximately 40%. The concentrations of the subunits in the assay were also well above the K d of 0.9 nM. The steady-state kinetic parameters of rC(W196R) in the presence of rRI(R333K) were then analyzed and compared with the kinetic parameters of free rC(W196R). As shown in Table III , the rRI(R333K):C(W196R) mixture exhibited a 1.6-fold decrease in V max . Furthermore, the rRI(R333K):C(W196R) mixture exhibited a 4-fold increase in K m(peptide) , indicating the kinetic parameters of rC(W196R) in the presence of rRI(R333K) were altered compared with those of free rC(W196R). The k cat /K m of rC(W196R) in the presence of rRI(R333K) versus that of the free rC(W196R) revealed a 6-fold decrease in catalytic efficiency. The interactions between rC(W196R) and RI(R333K) thus involve regions that lie predominantly outside of the substrate binding site.
DISCUSSION
The activation loop at the edge of the cleft interface on the large lobe of the catalytic subunit is an important segment for all protein kinases. As seen in Fig. 1 , many parts of the molecule communicate with this surface. His-87 from the small lobe, Arg-165 preceding the catalytic loop, and Lys-189 in ␤-strand 9 all contact the inward facing phosphate on Thr-197. In contrast, the residues that flank Thr-197 contribute directly to substrate/inhibitor binding. Leu-198 is a determinant for the P ϩ 1 site, whereas Trp-196, as shown here, is a critical part of the surface that recognizes the R subunit.
In many protein kinases this activation loop is only transiently assembled into its active conformation as a consequence of phosphorylation by a heterologous protein kinase (21) . In cAPK, however, this segment is assembled during the initial processing of the enzyme into a fully active protein phosphorylated on both Thr-197 and Ser-338 (41). Activation is then controlled through the binding and release of the regulatory subunit. The crystal structures of the C subunit reveal open 
and closed conformations, and the environment of this node at the edge of the cleft is certainly influenced by this movement with His-87 from the small lobe making contact only in the closed conformation (22) . However, these are relatively subtle conformational changes. Furthermore, the ledge of the large lobe on which substrates and inhibitors dock does not change as a consequence of substrate or inhibitor binding (42) . It is therefore a stable docking surface (43) . In contrast to C, there is much evidence to suggest that major conformational changes take place in the R subunit upon holoenzyme formation. As illustrated schematically in Fig. 7 , the R subunit exists in two distinct physiological states. Either it is bound to cAMP (the B-form) or it is in a complex with the catalytic subunit in the holoenzyme, R 2 C 2 (H-form) (44) . Considerable kinetic, biophysical, and mutational data indicate that there is tightly coupled communication between the two domains that correlates with the cooperative binding and release of cAMP. We know, for example, that only site B is exposed in the holoenzyme; whereas cAMP binding site A is masked (45, 46) . Binding of cAMP to site B leads to a conformational change that "opens up" site A. It is the binding of cAMP to site A that then leads to the dissociation of C (26) . The evidence presented here indicates that this is also the surface where Trp-196 interacts. cAMP and C, via the Trp-196 surface, both compete for the A domain of the R subunit.
The only crystallographic structure of R that has been solved to date is that of the monomeric RI deletion mutant (⌬1-91)RI (47) . The first 20 amino acids of (⌬1-91)RI, containing the autoinhibitory region, were not resolved in the structure, indicating that this region is disordered. In the full-length free R subunit, this segment is highly sensitive to proteolytic cleavage (48) , suggesting that it is probably flexible in the free R subunit. Both cAMP binding sites are saturated in this structure. Proteolytic and deletion mutational analysis of R demonstrated that neither the N terminus nor the B domain is required for high affinity binding to C (28, 49) . Thus, the region that contributes to high affinity binding to C is localized between the inhibitory consensus site and the end of the A domain. Several acidic sites within this region were protected by the C subunit from chemical modification by the water-soluble carbodiimide, 1-ethyl-3(3-dimethylaminopropyl)-carbodiimide⅐HCl, and were shown subsequently to be important for binding to the basic surface of C which surrounds the PRS2 node formed by Trp-196, His-87, and . Recently, an electrostatic interaction between Lys-213 on C and Glu-143 on RI was also identified. 2 As shown in Fig. 8 , the structure of the deletion mutant,(⌬1-91)rRI, reveals the orientation of the two cAMP binding domains as well as the molecular features of the cAMP binding sites. The structure also predicts that significant conformational changes would occur when cAMP is released. The extensive hydrogen bonding network surrounding the cAMP, for example, including the short helix between ␤-strands 6 and 7, will not exist in the absence of the nucleotide. When cAMP is removed, this network will be destroyed. However, when stripped of cAMP in vitro, the R subunit is much less stable, and the surface that docks to C can be readily accessed by both rC(WT) and rC(W196R) (34) . In the deletion mutant, however, where the B domain is no longer present, rC(W196R) can no longer form a stable complex. The cAMP binding site of the A domain is shielded in the full-length R subunit. Furthermore, the B domain is tightly associated, primarily through hydrophobic interactions, with the C-helix of the A domain. Thus, the B domain through its modulation of the C-helix controls access to cAMP binding site A. This is also consistent with recent deletion analysis of the A domain that shows the C terminus of the C-helix, residues 245-260 in domain A, is not essential for either cAMP binding or binding to C. When the B domain is absent, it is likely that the C-helix of domain A collapses onto the ␤-barrel, similar to the conformation it assumes in both the B domain and in the catabolite gene activation protein (CAP) (47, 51) . The best evidence for this comes from affinity labeling with 8-N 3 -cAMP. In the wild-type R subunit, Trp-260 is labeled by 8-N 3 -cAMP bound to site A (52, 53). In the deletion mutant, rRI(⌬260 -379), however, Tyr-244 is labeled instead (14) . As seen in Fig. 8 , labeling of Tyr-244, which is far from the cAMP binding pocket in full-length RI, requires this movement. In this conformation, where the normal signaling from the B domain is gone and Tyr-244 is close to cAMP, rC(W196R) cannot form an inhibited complex because the site that binds to C is shielded.
In rRI(R333K) the B domain is still present; however, because of its reduced affinity for cAMP, the site is empty. This mutant R subunit when stripped of cAMP can form a complex with rC(W196R) but the complex is incompletely formed. Based on 1) the altered kinetic behavior of rC(W196R) in the presence of stripped rRI(R333K), 2) the subnanomolar affinity of this complex measured by surface plasmon resonance, and 3) the fact that this active complex could be isolated by gel filtration, the partial inhibition of rC(W196R) in the presence of the various mutant forms of RI summarized in Table IV is most likely due to the formation of a complex that has undergone an initial docking event but cannot undergo the subsequent conformational switch that leads to complete inhibition, a step that correlates with occupancy of the active site cleft by the inhibitor segment (Fig. 9) . Whether the initial docking in wildtype C is through the inhibitor site at the cleft interface or through the PRS2 surface, in the final inhibited complex, both sites are filled and there must be a conformational change in R to enable both sites to be occupied simultaneously. Neither the initial docking nor this conformational switch can take place for rC(W196R) when cAMP is present. This is true for wild-type RI as well as for the mutant RI subunit. rC(W196R) can, however, form a stable complex with rRI(R333K), where cAMP binding site B is defective, once cAMP has been removed from site A. With this mutant, docking occurs via the PRS2 surface in the absence of cAMP; however, the switch mechanism that allows the inhibitor site to occupy the active site cleft is defective. The R subunit cannot change conformation so that the inhibitor recognition site is occupied. Thus, a stable complex is FIG. 9 . Model for the formation of partially inhibited holoenzyme complex. In the formation of wild-type holoenzyme, an initial docking event is followed by a conformational change that triggers the release of cAMP. This process requires both the inhibitor recognition site (IRS) and the PRS2 surface on C. When rC(W196R) was paired with cAMP-free rRI(R333K), a stable complex formed, but it was unable to undergo the final conformational switch (inset). This complex was partially active.
TABLE IV Inhibition of mutant RI-subunits with rC(W196R)
The percent inhibition of catalytic activity remaining in the presence of excess R-subunit is given. All of these mutant R-subunits inhibited rC(WT) linearly and stoichiometrically without prior stripping of cAMP. The subdomains of the R-subunit are indicated as follows beginning at the left with the N terminus: thin cross-hatch, dimerization domain with the two interchain disulfide bonds indicated as lines; small black segment, inhibitor site; cAMP site A, black; cAMP-binding site B, bold cross-hatch; cAMP, F.
formed, whereby the active site cleft is empty and capable of turning over substrates, albeit with less catalytic efficiency. The electrostatic interaction between Glu-143 and Lys-213 as well as the inability of the B deletion mutants to bind to rC(W196R) are consistent with this interpretation. The K d values for wild-type C and RI as well as for the two mutants, rC(W196R) and rRI(R333K), also indicate that the interaction with the PRS2 site provides most of the affinity for the interaction between RI and C.
To understand fully the interactions between the regulatory and catalytic subunits of cAPK at a molecular level, a high resolution crystallographic model of the tetrameric holoenzyme complex is required. Crystallographic models of mutant holoenzyme complexes such as that formed between rRI(R333K) and rC(W196R) will test the model shown in Fig. 9 , which may represent an intermediate in the holoenzyme-forming pathway.
